Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1CNS 1

Conditions

Zollinger-Ellison Syndrome 1Somatostatinoma 1Paraganglioma 1Insulinoma 1Glucagonoma 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1

Interventions

Specimen Handling 95Biopsy 79Magnetic Resonance Spectroscopy 74Paclitaxel 56Cyclophosphamide 53Cisplatin 53Radiotherapy 51Carboplatin 50Gemcitabine 43Bortezomib 38Irinotecan 37Taxes 32Fluorouracil 32Radiation 30veliparib 29Filgrastim 29Doxorubicin 29Vorinostat 27Oxaliplatin 27Leucovorin 27Ipilimumab 27alvocidib 26Cytarabine 26Temozolomide 25aldesleukin 24Rituximab 24fludarabine 23Etoposide 23Decitabine 23temsirolimus 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × NIH × Octreotide × Clear all
NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡